EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE Trial

Sripal Bangalore iD, R Dana Tomalty, Herman Kado iD, Sameh Sayfo iD, Adam Raskin, Arman Qamar iD, Andres Vargas Estrada, Kirema Garcia-Reyes iD, H Gabriel Lipshutz, Srinivas Yallapragada, Sabah Butty, Sagar Gandhi und 7 weitere

Circulation: Cardiovascular Interventions · 2025-11 · 18 (11)

DOI: 10.1161/circinterventions.125.015815 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2025-11. Verfasst von Sripal Bangalore und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, NYU Langone Health, New York (S. Bangalore). Hauptthemen laut MEDLINE: Pulmonary Embolism, Thrombectomy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mechanical thrombectomy offers a promising alternative to thrombolytic-based approaches for reducing thrombus burden and right heart strain in acute pulmonary embolism. This pivotal Food and Drug Administration–approval trial evaluated the safety and efficacy of the Symphony Thrombectomy System (Imperative Care, Inc, Campbell, CA) in acute intermediate-risk pulmonary embolism. METHODS: Patients with intermediate-risk pulmonary embolism (systolic blood pressure ≥90 mm Hg; right ventricle-to-left ventricle ratio >0.9) were enrolled without roll-ins. The primary safety end point was the rate of major adverse events within 48 hours, defined as a composite of all-cause major bleeding, device-related mortality, and serious device-related events, adjudicated by an academic independent safety board. The primary efficacy end point was the core laboratory–assessed mean change in right ventricle-to-left ventricle ratio from baseline to 48 hours. Prespecified performance goals were set for both. Exploratory end points included immediate postprocedure change in mean pulmonary artery pressure and change in modified Miller index at 48 hours. Safety was assessed in the intention-to-treat cohort and efficacy in the modified intention-to-treat cohort, excluding patients receiving nonstudy device treatments. RESULTS: Between December 2023 and May 2025, 109 patients were treated at 17 US centers (intention-to-treat), with 106 in the modified intention-to-treat cohort. The major adverse events rate was 0.9% (1/109), with an upper 97.5% CI of 5.7%, meeting the

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismThrombectomyHumansFemaleMaleMiddle AgedAgedTreatment OutcomeProspective StudiesTime FactorsRisk FactorsEquipment DesignRisk AssessmentArterial PressureVentricular Function, RightUnited StatesAged, 80 and over

Stichwörter der Autor:innen

anticoagulantshemorrhagemyocardial infarctionpulmonary embolismthrombectomy

Autor:innen und Institutionen

  • Division of Cardiology, NYU Langone Health, New York (S. Bangalore).
  • Radiology of Huntsville, Huntsville Hospital, AL (R.D.T.).
  • Department of Cardiovascular Medicine, Corewell Health William Beaumont Hospital, Royal Oak, MI (H.K., J.T.).
  • Department of Cardiovascular Medicine, Baylor Scott and White, The Heart Hospital, Plano, TX (S.S.).
  • Division of Endovascular Cardiovascular Medicine, Mercy Health, Inc, Cincinnati, OH (A.R.).
  • Division of Interventional Cardiology and Vascular Medicine, Endeavor Health (NorthShore University HealthSystem), Glenbrook Hospital, Glenview, IL (A.Q.).

ORCID-Profile: Sripal Bangalore, Herman Kado, Sameh Sayfo, Arman Qamar, Kirema Garcia-Reyes, David Dexter

Zitieren

APA

Bangalore, S., Tomalty, R. D., Kado, H., Sayfo, S., Raskin, A., Qamar, A., Vargas Estrada, A., Garcia-Reyes, K., Lipshutz, H. G., Yallapragada, S., Butty, S., Gandhi, S., Dexter, D., Trivax, J., Ali, F., Knox, M., Ramos, C., Al-Saghir, Y., & Bishay, V. (2025). Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE Trial. Circulation: Cardiovascular Interventions, 18(11). https://doi.org/10.1161/circinterventions.125.015815

Vancouver

Bangalore S, Tomalty RD, Kado H, Sayfo S, Raskin A, Qamar A, et al. Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE Trial. Circulation: Cardiovascular Interventions. 2025;18(11). doi:10.1161/circinterventions.125.015815

BibTeX
@article{Bangalore2025,
  author = {Bangalore, Sripal and Tomalty, R Dana and Kado, Herman and Sayfo, Sameh and Raskin, Adam and Qamar, Arman and Vargas Estrada, Andres and Garcia-Reyes, Kirema and Lipshutz, H Gabriel and Yallapragada, Srinivas and Butty, Sabah and Gandhi, Sagar and Dexter, David and Trivax, Justin and Ali, Farhan and Knox, Michael and Ramos, Christopher and Al-Saghir, Youssef and Bishay, Vivian},
  title = {Prospective Multicenter IDE Study of the Next-Generation Precision Aspiration Thrombectomy System for Intermediate-Risk Pulmonary Embolism: The SYMPHONY-PE Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {11},
  doi = {10.1161/circinterventions.125.015815}
}
Kostenlos starten →